Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.213
Filter
Add more filters

Publication year range
1.
FASEB J ; 38(3): e23467, 2024 Feb 15.
Article in English | MEDLINE | ID: mdl-38329325

ABSTRACT

Lumpy skin disease (LSD) is a severe animal infectious disease caused by lumpy skin disease virus (LSDV), inducing extensive nodules on the cattle mucosa or the scarfskin. LSDV genome encodes multiple proteins to evade host innate immune response. However, the underlying molecular mechanisms are poorly understood. In this study, we found that LSDV could suppress the expression of IFN-ß and interferon-stimulated genes (ISGs) in MDBK cells during the early stage of infection. Subsequently, an unbiased screen was performed to screen the LSDV genes with inhibitory effects on the type I interferon (IFN-I) production. ORF127 protein was identified as one of the strongest inhibitory effectors on the expression of IFN-ß and ISGs, meanwhile, the 1-43 aa of N-terminal of ORF127 played a vital role in suppressing the expression of IFN-ß. Overexpression of ORF127 could significantly promote LSDV replication through inhibiting the production of IFN-ß and ISGs in MDBK cells. Mechanism study showed that ORF127 specifically interacted with TBK1 and decreased the K63-linked polyubiquitination of TBK1 which suppressed the phosphorylation of TBK1 and ultimately decreased the production of IFN-ß. In addition, truncation mutation analysis indicated that the 1-43 aa of N-terminal of ORF127 protein was the key structural domain for its interaction with TBK1. In short, these results validated that ORF127 played a negative role in regulating IFN-ß expression through cGAS-STING signaling pathway. Taken together, this study clarified the molecular mechanism of ORF127 gene antagonizing IFN-I-mediated antiviral, which will helpfully provide new strategies for the treatment and prevention of LSD.


Subject(s)
Host-Pathogen Interactions , Interferon Type I , Lumpy skin disease virus , Protein Serine-Threonine Kinases , Animals , Cattle , Immunity, Innate , Interferon Type I/genetics , Interferon Type I/metabolism , Interferon-beta/metabolism , Lumpy skin disease virus/metabolism , Signal Transduction , Ubiquitination , Protein Serine-Threonine Kinases/metabolism
2.
J Pathol ; 262(2): 161-174, 2024 02.
Article in English | MEDLINE | ID: mdl-37929639

ABSTRACT

Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies targeting type XVII collagen (Col17) with the noncollagenous 16A (NC16A) ectodomain representing the immunodominant site. The role of additional extracellular targets of Col17 outside NC16A has not been unequivocally demonstrated. In this study, we showed that Col17 ectodomain-reactive patient sera depleted in NC16A IgG induced dermal-epidermal separation in a cryosection model indicating the pathogenic potential of anti-Col17 non-NC16A extracellular IgG. Moreover, injection of IgG targeting the murine Col17 NC14-1 domains (downstream of NC15A, the murine homologue of human NC16A) into C57BL/6J mice resulted in erythematous skin lesions and erosions. Clinical findings were accompanied by IgG/C3 deposits along the basement membrane and subepidermal blistering with inflammatory infiltrates. Disease development was significantly reduced in either Fc-gamma receptor (FcγR)- or complement-5a receptor-1 (C5aR1)-deficient mice. Inhibition of the neonatal FcR (FcRn), an atypical FcγR regulating IgG homeostasis, with the murine Fc fragment IgG2c-ABDEG, a derivative of efgartigimod, reduced anti-NC14-1 IgG levels, resulting in ameliorated skin inflammation compared with isotype-treated controls. These data demonstrate that the pathogenic effects of IgG targeting the Col17 domain outside human NC16A/murine NC15A are partly attributable to antibody-mediated FcγR- and C5aR1 effector mechanisms while pharmacological inhibition of the FcRn represents a promising treatment for BP. The mouse model of BP will be instrumental in further investigating the role of Col17 non-NC16A/NC15A extracellular epitopes and validating new therapies for this disease. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


Subject(s)
Collagen Type XVII , Pemphigoid, Bullous , Animals , Mice , Humans , Pemphigoid, Bullous/drug therapy , Receptors, IgG/genetics , Autoantigens/genetics , Non-Fibrillar Collagens/genetics , Mice, Inbred C57BL , Autoantibodies , Immunoglobulin G
3.
Mol Ther ; 32(4): 1061-1079, 2024 Apr 03.
Article in English | MEDLINE | ID: mdl-38382529

ABSTRACT

Complement-mediated diseases can be treated using systemic inhibitors. However, complement components are abundant in circulation, affecting systemic inhibitors' exposure and efficacy. Furthermore, because of complement's essential role in immunity, systemic treatments raise infection risk in patients. To address these challenges, we developed antibody fusion proteins combining the alternative-pathway complement inhibitor factor H (fH1-5) with an anti-C3d monoclonal antibody (C3d-mAb-2fH). Because C3d is deposited at sites of complement activity, this molecule localizes to tissue complement while minimizing circulating complement engagement. These fusion proteins bind to deposited complement in diseased human skin sections and localize to activated complement in a primate skin injury model. We further explored the pharmacology of C3d-mAb-2fH proteins in rodent models with robust tissue complement activation. Doses of C3d-mAb-2fH >1 mg/kg achieved >75% tissue complement inhibition in mouse and rat injury models while avoiding circulating complement blockade. Glomerular-specific complement inhibition reduced proteinuria and preserved podocyte foot-process architecture in rat membranous nephropathy, indicating disease-modifying efficacy. These data indicate that targeting local tissue complement results in durable and efficacious complement blockade in skin and kidney while avoiding systemic inhibition, suggesting broad applicability of this approach in treating a range of complement-mediated diseases.


Subject(s)
Complement Factor H , Kidney Diseases , Humans , Mice , Rats , Animals , Complement Factor H/genetics , Complement C3d/metabolism , Kidney Diseases/etiology , Antibodies , Complement Activation
4.
BMC Genomics ; 25(1): 196, 2024 Feb 19.
Article in English | MEDLINE | ID: mdl-38373902

ABSTRACT

Lumpy skin disease virus (LSDV) belongs to the genus Capripoxvirus and family Poxviridae. LSDV was endemic in most of Africa, the Middle East and Turkey, but since 2015, several outbreaks have been reported in other countries. In this study, we used whole genome sequencing approach to investigate the origin of the outbreak and understand the genomic landscape of the virus. Our study showed that the LSDV strain of 2022 outbreak exhibited many genetic variations compared to the Reference Neethling strain sequence and the previous field strains. A total of 1819 variations were found in 22 genome sequences, which includes 399 extragenic mutations, 153 insertion frameshift mutations, 234 deletion frameshift mutations, 271 Single nucleotide polymorphisms (SNPs) and 762 silent SNPs. Thirty-eight genes have more than 2 variations per gene, and these genes belong to viral-core proteins, viral binding proteins, replication, and RNA polymerase proteins. We highlight the importance of several SNPs in various genes, which may play an essential role in the pathogenesis of LSDV. Phylogenetic analysis performed on all whole genome sequences of LSDV showed two types of variants in India. One group of the variant with fewer mutations was found to lie closer to the LSDV 2019 strain from Ranchi while the other group clustered with previous Russian outbreaks from 2015. Our study highlights the importance of genomic characterization of viral outbreaks to not only monitor the frequency of mutations but also address its role in pathogenesis of LSDV as the outbreak continues.


Subject(s)
Lumpy Skin Disease , Lumpy skin disease virus , Animals , Cattle , Lumpy skin disease virus/genetics , Lumpy Skin Disease/epidemiology , Lumpy Skin Disease/genetics , Phylogeny , Genomics , Disease Outbreaks
5.
Cancer Sci ; 115(1): 17-23, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38048779

ABSTRACT

Plakophilin 3 (PKP3), a component of desmosome, is aberrantly expressed in many kinds of human diseases, especially in cancers. Through direct interaction, PKP3 binds with a series of desmosomal proteins, such as desmoglein, desmocollin, plakoglobin, and desmoplakin, to initiate desmosome aggregation, then promotes its stability. As PKP3 is mostly expressed in the skin, loss of PKP3 promotes the development of several skin diseases, such as paraneoplastic pemphigus, pemphigus vulgaris, and hypertrophic scar. Moreover, accumulated clinical data indicate that PKP3 dysregulates in diverse cancers, including breast, ovarian, colon, and lung cancers. Numerous lines of evidence have shown that PKP3 plays important roles in multiple cellular processes during cancer progression, including metastasis, invasion, tumor formation, autophagy, and proliferation. This review examines the diverse functions of PKP3 in regulating tumor formation and development in various types of cancers and summarizes its detailed mechanisms in the occurrence of skin diseases.


Subject(s)
Neoplasms , Plakophilins , Skin Diseases , Humans , Desmosomes/metabolism , Neoplasms/metabolism , Plakophilins/genetics , Plakophilins/metabolism
6.
Expert Rev Mol Med ; 26: e15, 2024 Apr 15.
Article in English | MEDLINE | ID: mdl-38621674

ABSTRACT

In mammals, the skin acts as a barrier to prevent harmful environmental stimuli from entering the circulation. CYP450s are involved in drug biotransformation, exogenous and endogenous substrate metabolism, and maintaining the normal physiological function of the skin, as well as facilitating homeostasis of the internal environment. The expression pattern of CYP450s in the skin is tissue-specific and thus differs from the liver and other organs. The development of skin topical medications, and knowledge of the toxicity and side effects of these medications require a detailed understanding of the expression and function of skin-specific CYP450s. Thus, we summarized the expression of CYP450s in the skin, their function in endogenous metabolic physiology, aberrant CYP450 expression in skin diseases and the influence of environmental variables and medications. This information will serve as a crucial foundation for future studies on the skin, as well as for the design and development of new drugs for skin diseases including topical medications.


Subject(s)
Cytochrome P-450 Enzyme System , Skin , Humans , Skin/metabolism , Cytochrome P-450 Enzyme System/metabolism , Cytochrome P-450 Enzyme System/genetics , Animals , Skin Diseases/metabolism
7.
J Virol ; 97(11): e0139423, 2023 Nov 30.
Article in English | MEDLINE | ID: mdl-37905838

ABSTRACT

IMPORTANCE: Lumpy skin disease virus (LSDV) has a complex epidemiology involving multiple strains, recombination, and vaccination. Its DNA genome provides limited genetic variation to trace outbreaks in space and time. Sequencing of LSDV whole genomes has also been patchy at global and regional scales. Here, we provide the first fine-grained whole genome sequence sampling of a constrained LSDV outbreak (southeastern Europe, 2015-2017), which we analyze along with global publicly available genomes. We formally evaluate the past occurrence of recombination events as well as the temporal signal that is required for calibrating molecular clock models and subsequently conduct a time-calibrated spatially explicit phylogeographic reconstruction. Our study further illustrates the importance of accounting for recombination events before reconstructing global and regional dynamics of DNA viruses. More LSDV whole genomes from endemic areas are needed to obtain a comprehensive understanding of global LSDV dispersal dynamics.


Subject(s)
Genome, Viral , Lumpy Skin Disease , Lumpy skin disease virus , Animals , Cattle , Disease Outbreaks , DNA, Viral/genetics , Europe/epidemiology , Lumpy Skin Disease/epidemiology , Lumpy Skin Disease/virology , Lumpy skin disease virus/genetics , Phylogeny
8.
J Virol ; 97(10): e0072323, 2023 10 31.
Article in English | MEDLINE | ID: mdl-37737587

ABSTRACT

IMPORTANCE: Lumpy skin disease virus (LSDV) is the causative agent of an economically important cattle disease which is notifiable to the World Organisation for Animal Health. Over the past decades, the disease has spread at an alarming rate throughout the African continent, the Middle East, Eastern Europe, the Russian Federation, and many Asian countries. While multiple LDSV whole genomes have made further genetic comparative analyses possible, knowledge on the protein composition of the LSDV particle remains lacking. This study provides for the first time a comprehensive proteomic analysis of an infectious LSDV particle, prompting new efforts toward further proteomic LSDV strain characterization. Furthermore, this first incursion within the capripoxvirus proteome represents one of very few proteomic studies beyond the sole Orthopoxvirus genus, for which most of the proteomics studies have been performed. Providing new information about other chordopoxviruses may contribute to shedding new light on protein composition within the Poxviridae family.


Subject(s)
Lumpy Skin Disease , Lumpy skin disease virus , Proteomics , Viral Proteins , Animals , Cattle , Lumpy Skin Disease/virology , Lumpy skin disease virus/metabolism , Virion/metabolism , Viral Proteins/analysis , Viral Proteins/metabolism , Proteome/analysis , Proteome/metabolism
9.
Microb Pathog ; 186: 106485, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38052279

ABSTRACT

Lumpy skin disease (LSD) is an emerging transboundary viral disease of livestock animals which was first reported in 1929 in Zambia. Although LSD is a neglected disease of economic importance, it extends a direct impact on the international trade and economy in livestock-dependent countries. Lumpy skin disease virus (LSDV) has been endemic in African countries, where several outbreaks have been reported previously. However, the virus has spread rapidly across the Middle East in the past two decades, reaching Russia and, recently, the Asian subcontinent. With unprecedented cluster outbreaks being reported across Asian countries like India, China, Nepal, Bangladesh, and Pakistan, LSDV is certainly undergoing an epidemiological shift and expanding its geographical footprint worldwide. Due to high mortality among livestock animals, the recent LSD outbreaks have gained attention from global regulatory authorities and raised serious concerns among epidemiologists and veterinary researchers. Despite networked global surveillance of the disease, recurrent LSD cases pose a threat to the livestock industry. Hence, this review provides recent insights into the LSDV biology by augmenting the latest literature associated with its pathogenesis, transmission, current intervention strategies, and economic implications. The review critically examines the changing epidemiological footprint of LSDV globally, especially in relation to developing countries of the Asian subcontinent. We also speculate the possible reasons contributing to the ongoing LSD outbreaks, including illegal animal trade, climate change, genetic recombination events between wild-type and vaccine strains, reversion of vaccine strains to virulent phenotype, and deficiencies in active monitoring during the COVID-19 pandemic.


Subject(s)
Lumpy Skin Disease , Lumpy skin disease virus , Animals , Cattle , Humans , Lumpy Skin Disease/epidemiology , Lumpy Skin Disease/prevention & control , Commerce , Pandemics , Internationality , Lumpy skin disease virus/genetics , Disease Outbreaks/veterinary , Vaccines, Attenuated , Pakistan , Phylogeny
10.
Exp Dermatol ; 33(3): e15050, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38469984

ABSTRACT

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic mutation) syndrome is a novel autoinflammatory, late-onset, disorder first identified in 2020. It is caused by mutations in the UBA1 gene. The most prominent clinical features reported by VEXAS patients are cutaneous and haematological, having characteristic skin features reported as the initial presenting findings of the disease. VEXAS is a severe and treatment-resistant condition with high morbidity and mortality rates. Here, we examine all case reports and case series of VEXAS syndrome through March 2023 focusing on those presenting cutaneous manifestations. We discuss these manifestations and their reported treatment strategies. In many cases, it might be first suspected and diagnosed by dermatologists, highlighting their vital role in initiating timely multidisciplinary care.


Subject(s)
Hereditary Autoinflammatory Diseases , Myelodysplastic Syndromes , Skin Diseases, Genetic , Humans , Mutation , Skin , Syndrome , Hereditary Autoinflammatory Diseases/genetics , Hereditary Autoinflammatory Diseases/therapy
11.
FASEB J ; 37(5): e22902, 2023 05.
Article in English | MEDLINE | ID: mdl-37014316

ABSTRACT

The monkeypox epidemic has attracted global attention to poxviruses. The cytoplasmic replication of poxviruses requires extensive protein synthesis, challenging the capacity of the endoplasmic reticulum (ER). However, the role of the ER in the life cycle of poxviruses is unclear. In this study, we demonstrate that infection with the lumpy skin disease virus (LSDV), a member of the poxvirus family, causes ER stress in vivo and in vitro, further facilitating the activation of the unfolded protein response (UPR). Although UPR activation aids in the restoration of the cellular environment, its significance in the LSDV life cycle remains unclear. Furthermore, the significance of ER imbalance for viral replication is also unknown. We show that LSDV replication is hampered by an unbalanced ER environment. In addition, we verify that the LSDV replication depends on the activation of PERK-eIF2α and IRE1-XBP1 signaling cascades rather than ATF6, implying that global translation and reduced XBP1 cleavage are deleterious to LSDV replication. Taken together, these findings indicate that LSDV is involved in the repression of global translational signaling, ER chaperone transcription, and ATF6 cleavage from the Golgi into the nucleus, thereby maintaining cell homeostasis; moreover, PERK and IRE1 activation contribute to LSDV replication. Our findings suggest that targeting UPR elements may be applied in response to infection from LSDV or even other poxviruses, such as monkeypox.


Subject(s)
Lumpy skin disease virus , Mpox (monkeypox) , Animals , Cattle , Humans , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Lumpy skin disease virus/metabolism , Mpox (monkeypox)/metabolism , Signal Transduction , Unfolded Protein Response , Endoplasmic Reticulum Stress/physiology , Endoplasmic Reticulum/metabolism , Activating Transcription Factor 6/metabolism
12.
Vet Res ; 55(1): 33, 2024 Mar 16.
Article in English | MEDLINE | ID: mdl-38493160

ABSTRACT

Lumpy skin disease virus (LSDV) infection is a major socio-economic issue that seriously threatens the global cattle-farming industry. Here, a recombinant virus LSDV-ΔTK/EGFP, expressing enhanced green fluorescent protein (EGFP), was constructed with a homologous recombination system and applied to the high-throughput screening of antiviral drugs. LSDV-ΔTK/EGFP replicates in various kidney cell lines, consistent with wild-type LSDV. The cytopathic effect, viral particle morphology, and growth performance of LSDV-ΔTK/EGFP are consistent with those of wild-type LSDV. High-throughput screening allowed to identify several molecules that inhibit LSDV-ΔTK/EGFP replication. The strong inhibitory effect of theaflavin on LSDV was identified when 100 antiviral drugs were screened in vitro. An infection time analysis showed that theaflavin plays a role in the entry of LSDV into cells and in subsequent viral replication stages. The development of this recombinant virus will contribute to the development of LSDV-directed antiviral drugs and the study of viral replication and mechanisms of action.


Subject(s)
Cattle Diseases , Lumpy Skin Disease , Lumpy skin disease virus , Animals , Cattle , Antiviral Agents/pharmacology , High-Throughput Screening Assays/veterinary , Virus Replication , Cell Line
13.
Virus Genes ; 60(2): 159-172, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38347303

ABSTRACT

Lumpy skin disease (LSD) caused by LSD virus is a WOAH notifiable, high-impact, transboundary poxviral disease of bovines. The first official report of LSDV in India is from Odisha state during August 2019. Since then, cases have been reported from many states including Tamil Nadu, a Southern state of India. The present study deals with isolation and molecular characterization of LSDV from Tamil Nadu during the period August 2020 to July 2022. LSDV was isolated in embryonated chicken eggs (ECE) and BHK 21 cells and was characterized based on P32, RPO30, and GPCR genes. The phylogenetic analysis revealed that Tamil Nadu isolates from India are closely related to other Indian strains, Kenyan strains and strains from neighboring countries such as Bangladesh, Nepal, and Myanmar confirming the common exotic source for the transboundary spread across borders. The presence of unique signature of amino acid (aa) at specific positions (A11, T12, T34, S99, and P199) in the GPCR sequence confirmed the identity of LSDV. A twelve nucleotide (nt94-105) insertion and corresponding aa (TILS) at 30-33 position was found in GPCR sequence and characteristic amino acid proline at 98 position (P98) in the RPO30 gene sequence of our isolates was similar to strains from Bangladesh, Nepal, and Myanmar. Further, dissimilarity of our isolates from Neethling like vaccine strains confirms the circulation of virulent filed strains responsible for the outbreaks.


Subject(s)
Lumpy skin disease virus , Animals , Cattle , Lumpy skin disease virus/genetics , India/epidemiology , Phylogeny , Kenya , Disease Outbreaks , Amino Acids/genetics
14.
J Cutan Pathol ; 51(2): 163-169, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37853944

ABSTRACT

BACKGROUND: IgG4-related disease (IgG4-RD) represents a recently characterized multisystemic fibroinflammatory condition that can manifest a spectrum of skin findings (IgG4-related skin disease; IgG4-RSD). Histopathologic and immunohistochemical criteria have been proposed; however, the specificity of these criteria merits scrutiny given the potential histopathologic overlap of IgG4-RSD and both neoplastic and inflammatory skin conditions featuring lymphoplasmacytic infiltrates (IgG4-RSD mimics). This study sought to assess the specificity of the criteria by quantifying the frequency by which an expanded spectrum of IgG4-RSD mimics meet proposed thresholds. METHODS: Following IRB approval, a total of 69 cases of IgG4-RD mimics, representing 14 different diagnoses featuring plasma cells, were reviewed and analyzed for the following histopathologic and immunohistochemical features: (i) maximum IgG4+ count/high-powered field (hpf) >200; (ii) IgG4/IgG ratio >0.4 averaged over 3 hpfs; (iii) IgG4+ count >10 per hpf. RESULTS: Screening for IgG4-RSD by histopathologic criteria demonstrated the high frequency of lymphoplasmacytic infiltrates, contrasted with the rarity of storiform fibrosis (only one case of erythema elevatum diutinum [EED]) and obliterative phlebitis (0 cases). By immunohistochemical criteria, the analysis revealed that no cases exceeded 200 IgG4+ cells; 13% (9/69) cases demonstrated an IgG4/IgG ratio of >0.4 averaged over 3 hpfs; and 23% (16/69) cases demonstrated a mean IgG4+ count of >10 per hpf. CONCLUSION: Application of proposed IgG4-RSD histopathologic criteria to an expanded spectrum of potential IgG4-RSD mimics (to include cutaneous marginal zone lymphoma, syphilis, necrobiosis lipoidica, lichen sclerosus, ALHE, psoriasis, lymphoplasmacytic plaque, EED, and erosive pustular dermatosis), highlights the relative nonspecificity of lymphoplasmacytic infiltrates contrasted with the stringency of storiform fibrosis and obliterative fibrosis. Furthermore, an IgG4+ cell count of >10 per hpf and an IgG4/IgG ratio of >0.4 are not specific to IgG4-RSD alone. In the appropriate clinical context for IgG4-RSD, histopathologic features still represent the entry threshold for diagnosis consideration, which then allows for further screening by immunohistochemical criteria.


Subject(s)
Immunoglobulin G4-Related Disease , Skin Diseases , Humans , Immunoglobulin G4-Related Disease/diagnosis , Immunoglobulin G4-Related Disease/pathology , Skin/pathology , Plasma Cells/pathology , Skin Diseases/diagnosis , Skin Diseases/pathology , Fibrosis , Immunoglobulin G/analysis
15.
Contact Dermatitis ; 90(2): 116-125, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37735996

ABSTRACT

BACKGROUND: Rubber accelerators are used in the production of rubber gloves and may cause contact allergy. OBJECTIVES: To estimate long-term trend and prevalence of contact allergy to rubber accelerators for a 30-year period in Denmark, high-risk occupations, and exposures. METHODS: Data from all patients with contact dermatitis consecutively patch tested at the department of Skin and Allergy Gentofte hospital with the rubber accelerators from the European baseline series (EBS) from 1990 to 2019, were analysed. Further, patients under suspicion of rubber accelerator contact allergy were additionally patch-tested with rubber accelerators from the specialised rubber series from 2005 to 2019 and these were additional extracted. RESULTS: The overall prevalence of contact allergy to one or more of the rubber accelerators from the EBS series was 2.7% with a significant decline in the first 12-years, followed by a stable frequency in the past 18-years. Associations with occupational contact dermatitis, hand dermatitis, and leg/foot dermatitis were found. Wet-work occupations were most often affected and gloves the most frequent exposure. CONCLUSIONS: Contact allergy to one or more of the rubber accelerators from the EBS is frequent and has been unchanged for several decades, which calls for prevention.


Subject(s)
Dermatitis, Allergic Contact , Dermatitis, Occupational , Eczema , Latex Hypersensitivity , Humans , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Allergic Contact/etiology , Rubber/adverse effects , Patch Tests/adverse effects , Dermatitis, Occupational/etiology , Dermatitis, Occupational/complications , Latex Hypersensitivity/epidemiology , Eczema/epidemiology , Eczema/complications , Denmark/epidemiology
16.
Adv Exp Med Biol ; 1447: 91-104, 2024.
Article in English | MEDLINE | ID: mdl-38724787

ABSTRACT

Atopic dermatitis (AD) is a chronic inflammatory disorder that affects over 30 million people in the United States. Given the large and growing prevalence of AD, the associated economic burden is significant. It has been estimated that AD costs over $5 billion dollars annually. These costs include both direct and indirect costs. Direct costs include prescription medicines, visits to health-care providers, hospitalizations, and transportation. Indirect costs include missed days or lost productivity at work or school, career modification, and reduced quality of life. Understanding and measuring these costs can be accomplished through rigorous economic evaluation, which is the organized process of considering inputs and outcomes of various activities. Economic evaluation has been used to contextualize the burden of AD in society. It has also been used to inform patients, providers, and other stakeholders on how to deliver the most evidence-based, efficient way possible. Understanding the economic impact of atopic dermatitis is an important aspect of delivering high-quality care.


Subject(s)
Cost of Illness , Dermatitis, Atopic , Health Care Costs , Quality of Life , Dermatitis, Atopic/economics , Humans , United States/epidemiology
17.
Adv Exp Med Biol ; 1447: 1-10, 2024.
Article in English | MEDLINE | ID: mdl-38724779

ABSTRACT

Atopic dermatitis (AD) is a chronic relapsing condition that is characterized by itching and redness of the skin. Our modern usage of atopic dermatitis dates back to 1933, when Wise and Sulzberger first coined the term to signify the disease's close association with other respiratory atopy, such as bronchial asthma and allergic rhinitis. A recent systematic review of 69 cross-sectional and cohort studies has confirmed that AD is now a worldwide phenomenon with lifetime AD prevalences of well over 20% in many affluent country settings. Although there is no obvious consistent overall global trend in the prevalence of AD, studies have shown that climate, urbanization, lifestyle, and socioeconomic class influence the prevalence of atopic dermatitis. Despite the pervasiveness of the disease, an understanding of atopic dermatitis has been hampered by a number of factors. Data suggests that extrinsic environmental factors work in concert with intrinsic immune mechanism and genetic factors to drive disease progression. With such a complex etiology, management of atopic dermatitis currently at best achieves symptomatic control rather than cure. This approach poses a significant burden on healthcare resources, as well as patients' quality of life. Current management methods of AD often involve a combination of non-pharmacologic modalities and prescription medications. Though they can be effective when employed, there are significant barriers to treatment for patients including time, costs, and medication side effects. Our aim, throughout this text, is to explore the complexities of AD, providing the healthcare provider with tips and tricks to improve patient care and satisfaction and the most current trends and treatment approaches on the horizon.


Subject(s)
Dermatitis, Atopic , Humans , Dermatitis, Atopic/epidemiology , Prevalence , Quality of Life , Risk Factors
18.
Adv Exp Med Biol ; 1447: 69-81, 2024.
Article in English | MEDLINE | ID: mdl-38724785

ABSTRACT

Atopic dermatitis is a chronic skin condition that has significant psychosocial and quality-of-life impact. The condition causes physical discomfort, emotional distress, embarrassment, social stigma, and daily activity limitation. In an effort to assess these aspects of disease burden, quality-of-life measurement tools were developed. Through use of these tools, we have expanded our knowledge of the psychosocial and quality-of-life burden of this condition. A variety of quality of assessment tools exist, yet there is no consensus on which tool is best suited to assess the quality-of-life impact of atopic dermatitis. Research studies assessing quality-of-life in atopic dermatitis patients utilize a variety of quality-of-life measurement tools; this complicates comparisons across research studies. Though comparison across studies is difficult, the data echoes tremendous overall burden of disease, especially pertaining to psychosocial status and life quality.


Subject(s)
Dermatitis, Atopic , Quality of Life , Dermatitis, Atopic/psychology , Humans , Quality of Life/psychology , Cost of Illness , Surveys and Questionnaires , Social Stigma
19.
Pediatr Dermatol ; 41(1): 80-83, 2024.
Article in English | MEDLINE | ID: mdl-37345838

ABSTRACT

Congenital insensitivity to pain (CIP) is a rare phenotype characterized by the inability to perceive pain stimuli with subsequent self-injuries, whereas CIP associated with anhidrosis (CIPA) is an overlapping phenotype mainly characterized by insensitivity to noxious stimuli and anhidrosis. CIP is primarily associated with pathogenetic variants in the SCN9A gene while CIPA is associated with pathogenetic variants in NGF and NRTK genes. However, in recent years, a significant overlap between these two disorders has been observed highlighting the presence of anhidrosis in SCN9A variants. We report the cases of two siblings (age 4 and 6 years) born from consanguineous parents presenting with a previously undescribed phenotype due to a novel pathogenic variant in SCN9A clinically characterized by congenital insensitivity to pain, anhidrosis, and mild cognitive impairment.


Subject(s)
Channelopathies , Cognitive Dysfunction , Hereditary Sensory and Autonomic Neuropathies , Hypohidrosis , Indoles , Pain Insensitivity, Congenital , Propionates , Humans , Child, Preschool , Child , Pain Insensitivity, Congenital/genetics , Hypohidrosis/genetics , Mutation , Receptor, trkA/genetics , Pain/genetics , Cognitive Dysfunction/genetics , Hereditary Sensory and Autonomic Neuropathies/genetics , NAV1.7 Voltage-Gated Sodium Channel/genetics
20.
J Fish Dis ; 47(1): e13870, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37800856

ABSTRACT

Since 2014, Atlantic salmon (Salmo salar L.) displaying clinical signs of red skin disease (RSD), including haemorrhagic and ulcerative skin lesions, have been repeatedly observed in Swedish rivers. Although the disease has since been reported in other countries, including Norway, Denmark, Ireland and the UK, no pathogen has so far been conclusively associated with RSD. In this study, the presence of 17 fish pathogens was investigated through qPCR in 18 returning Atlantic salmon with clinical signs of the disease in rivers in Sweden and Norway between 2019 and 2021. Several potential pathogens were repeatedly detected, including a protozoan (Ichthyobodo spp.), an oomycete (Saprolegnia spp.) and several bacteria (Yersinia ruckeri, Candidatus Branchiomonas cysticola, Aeromonas spp.). Cultivation on different media from ulcers and internal organs revealed high concentrations of rod-shaped bacteria typical of Aeromonadaceae. Multilocus phylogenetic analysis of different clones and single gene phylogenies of sequences obtained from the fish revealed concurrent isolation of several bacterial strains belonging to the species A. bestiarum, A. piscicola and A. sobria. While these bacterial infections may be secondary, these findings are significant for future studies on RSD and should guide the investigation of future outbreaks. However, the involvement of Aeromonas spp. as putative primary etiological agents of the disease cannot be ruled out and needs to be assessed by challenge experiments.


Subject(s)
Aeromonas , Fish Diseases , Salmo salar , Skin Ulcer , Animals , Aeromonas/genetics , Phylogeny , Fish Diseases/epidemiology , Fish Diseases/microbiology , Skin Ulcer/veterinary
SELECTION OF CITATIONS
SEARCH DETAIL